One field of immuno-oncology which is called the adoptive cell therapy has gathered a lot of interest recently, particularly Chimeric Antigen Receptor T (CAR-T) therapies. CAR-T therapy potentially provides a highly specific standard of care therapy in hematological malignancies which are difficult to treat via conventional measures. Most of CAR-T therapies in development target CD19, a B cell surface protein which is expressed throughout B cell development. Creative Biolabs has established a set of validated CD19 positive cell line derived tumor xenograft (CDX) in humanized mouse models for evaluation of novel CAR-T therapies for both efficacy and safety testing, aiming at assisting you in studies on immunotherapy.
CD19 - The Main CAR-T Therapy Target
CAR-T is a novel immunotherapy that targets specific tumor-associated antigens. In CAR-T treatments, T cells are extracted from a patient and genetically modified in vitro to identify a specific tumor-associated antigen. Subsequently, CAR-T cells that proliferated outside the patient are reinfused, and effectively give the patient a “living drug”. CAR-T cells then multiply and selectively attack and kill only those cells displaying the specific surface antigen, ensuring high tumor specificity. As CAR-T therapies have rapidly developed into approved immuno-oncology agents, it is necessary to validate cost-effective efficacy and treatment security via in vivo preclinical models.
B-lymphocyte antigen CD19, also known as CD19 (Cluster of Differentiation 19), is expressed on follicular dendritic cells and B cells. Indeed, it is present on B cells from the earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. B cell-specific CD19 phosphoglycoprotein is one of the surface molecules that form the antigen receptor and form a complex on B lymphocytes. CD19 predominantly acts as a B cell co-receptor in conjunction with the other two surface molecules CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. The cytoplasmic tail of CD19 turns to be phosphorylated upon activation, which results in binding by Src-family kinases and recruitment of PI-3 kinase. These characteristics make CD19 the main target for CAR-T therapies in hematological malignancies, such as B cell lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
Now Available in Creative Biolabs
As CAR-T therapies have rapidly developed into approved immuno-oncology agents, it is necessary to validate cost-effective efficacy and treatment security via in vivo preclinical models.
We provide two distinct well-established platforms for in vivo CAR-T evaluation system:
Utilizing CD19 Positive CDX to Evaluate CAR-T Therapies
As validated preclinical models are needed to conduct forward preclinical research in this fast-paced area of immunotherapy, CD19 positive cell line derived tumor xenograft enables a quick and effective approach to CAR-T evaluation. Creative Biolabs has established a wide range of well-characterized CD19 positive cell line derived xenograft in humanized mouse models and can provide an ideal platform for your research on immunotherapy.
Why choose us?
Our Magic™ mouse models with CD19 positive cell line derived tumor xenograft is highly sensitive to CAR-T CD19 targeting and shows validated model survival following CAR-T cell therapy. In Creative Biolabs, a team of senior scientists focused on humanized mouse models can support you to evaluate novel CAR-T therapies in a timely and cost-effective method. What's more, we also established comprehensive in vitro immunomodulation assessment service using various approaches. Please feel free to contact us for more details.
Other Humanized Mouse Based Tumor Models you may be interested in are also available in Creative Biolabs:
Equipped with advanced technologies, Creative Biolabs can offer other common rodent tumor models for our customers all over the world:
For Research Use Only.
